



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org

Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2023/S-LDF094

May 20, 2023

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001,

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code No. 524768

With reference to the above subject, please be informed that the Board of Directors at its meeting held today, has transacted the following business.

1. The Board has considered and approved the Audited Standalone Financial Results of the company for the fourth quarter / financial year ended March 31, 2023.

The Audited Financial Results of the Company for the year ended March 31, 2023, will be made available on the website of the Company: <http://www.ebnl.org>, in due compliance with the Listing Regulations.

2. The Board took on record the Auditors' Report issued by the Statutory Auditors for the Audited Standalone Financial Result of the Company for the Financial Year 2022 – 2023
3. Declaration pursuant to Regulation 33 (3) (d) of SEBI [LODR] Regulations, 2015.
4. The Board also decided to hold the Annual General Meeting, the date of which will be declared shortly.
5. General discussion about other matters as per the agenda of the meeting.

The Board meeting commenced at 02.30 pm and concluded at 04.30 pm.

You are kindly requested to take same on record.

Thanking you,
Yours faithfully,

For Emmessar Biotech & Nutrition Limited


Jeyavel B. Nadar
Executive Director
DIN No. 08163899
Encl: Financial Results



Regd. Office & Factory: Plot No. T-3/2, MIDC Area, Talaja – 410208. Dist. Raigad. Maharashtra.
Email: enquiries@ebnl.org Website: www.ebnl.org



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2023/S-LDF094/A

May 20, 2023

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeejebhoy Towers
Dalal Street, Fort, Mumbai – 400 001,

Dear Sir /Madam,

Sub: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Audited Standalone Financial Results of the Company for the fourth quarter / year ended March 31, 2023.

Ref: Scrip Code No. 524768


Pursuant to provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors at its meeting held today, May 21, 2023, has approved the Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2023.

We are enclosing herewith the following:

1. The Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2023
2. The Independent Auditors' Report dated May 21, 2023, issued by the Statutory Auditors for the Audited Standalone Financial Result of the Company for the Financial year 2022-2023. The Results will be made available on the website of the Company: www.ebnl.org.
3. Declaration pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

You are kindly requested to take same on record.

Thanking you,
Yours faithfully,
For Emmessar Biotech & Nutrition Limited


Jeyavel B. Nadar
Executive Director
DIN No. 08163899



Encl: Financial Results, Independent Auditors' Report & Declaration UR 33(3)

Regd. Office & Factory: Plot No. T-3/2, MIDC Area, Taloja – 410208. Dist. Raigad. Maharashtra.
Email: enquiries@ebnl.org Website: www.ebnl.org



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2023/S-LDF094/B

May 20, 2023

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeejebhoy Towers
Dalal Street, Fort, Mumbai – 400 001,

Dear Sir / Madam,

Sub: Declaration Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations.

Ref: Scrip Code No. 524768

In compliance with the provision of Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we hereby declare that M/s V. Sankar Aiyar & Co., Statutory Auditors of the Company, have issued Audit Report dated May 20, 2023, with Unmodified Opinion of the Audited Financial Results of the company (Standalone), for the quarter / year ended March 31, 2023.

You are kindly requested to take same on record.

Thanking you,
Yours faithfully,
For Emmessar Biotech & Nutrition Limited

Jeyavel B. Nadar
Executive Director
DIN No. 08163899



Encl: Financial Results, Independent Auditors Report

EMMESSAR BIOTECH & NUTRITION LTD						
Regd Office: Plot No. T-3/2, MIDC, Taloja, Raigard District, Maharashtra - 410 208						
CIN: L24110MH1992PLC06594229						
AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2023						Rs. In lacs
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		See Note 6	Unaudited	See Note 6	Audited	Audited
	PART A					
1	Revenue from Operations	31.64	42.73	14.64	101.92	36.49
2	Other Income	41.59	44.48	70.60	175.07	191.87
	Total Income A (1 + 2)	73.23	87.21	85.24	276.99	228.37
	PART B					
3	Expenses					
	(a) Cost of material consumed	2.07	2.13	0.85	6.88	1.65
	(b) Purchase of Stock-trade	11.68	18.98	0.00	37.66	11.00
	(c) Change in inventories of Finished goods	(0.14)	(5.00)	4.99	(4.56)	(0.09)
	(d) Employee Benefit Expenses	20.21	25.39	18.05	83.71	77.31
	(e) Depreciation & amortisation of Assets	2.37	2.37	3.69	9.36	9.23
	(f) Other Expenditure	13.11	18.37	8.58	47.25	36.12
	Total Expenses (a to f)	49.30	62.24	36.16	180.30	135.22
4	Profit from operations from exceptional items and taxes (A - B)	23.93	24.97	49.08	96.69	93.15
5	Exceptional Items	0.00	0.00	0.00	0.00	0.00
6	Profit / loss before tax (4 - 5)	23.93	24.97	49.08	96.69	93.15
7	Tax Expense					
	1. Current tax	5.00	(10.00)	(19.00)	(14.91)	(19.00)
	2. Deferred tax asset / (Liability)	0.30	(17.17)	(2.22)	(21.18)	(2.22)
	3. Excess / (Short) provision of earlier years	4.01	0.00	(19.39)	3.55	(19.39)
	4. MAT Credit available	(13.55)	0.00	(5.00)	(13.77)	(5.00)
8	Net Profit / (loss) after tax (6 - 7)	19.69	(2.20)	3.47	50.38	47.54
9	Other comprehensive income	0.82	0.00	0.72	0.82	0.72
10	Total comprehensive income for the period and other comprehensive income	18.87	(2.20)	2.75	49.56	46.82
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61
	Face Value of the share	10.00	10.00	10.00	10.00	10.00
12	Earnings per Equity Share					
	a) Basic	0.38	(0.04)	0.05	0.99	0.94
	b) Diluted	0.38	(0.04)	0.05	0.99	0.94

NOTES

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 20th May 2023.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS-34) as prescribed under Section 133 of Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rule 2015 and the Companies (Indian Accounting Standards) Amendments Rule 2016 as amended thereafter.
- During the year the company operated in two segments ie. Healthcare and Rent on leasehold land.
- The audit as required under Regulation 33 of the SEBI (Listing obligation and disclosure agreements) regulations, 2015 has been completed by the Auditors of the company.
- No Investors complaints were received as of Quarter ended 31st March 2023
- The figures for the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the year ended March 31, 2023 and the unaudited figures of the nine month ended December 31, 2022. The figures for the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the year ended March 31, 2023 and the unaudited figures of the nine month ended December 31, 2022
- Previous years' figures have been regrouped wherever considered necessary.

Place: Mumbai
Date : 20-05-2023

for Emmessar Biotech & Nutrition Ltd


Jeyavel B. Nadar
Executive Director & CFO
DIN No. 08163899



EMMESSAR BIOTECH & NUTRITION LTD


Quarter and Year ended Segment wise Revenue Results and
Capital Employed under Clause 41 of the Listing Agreement.

[Rs. In Lacs]

	Quarter ended			Year Ended	
	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	See Note 6	Unaudited	See Note 6	Audited	Audited
1. Segment Revenue (Net Sales / Income)					
a. Healthcare	31.64	42.73	14.64	101.92	36.49
b. Rent on Leasehold land	37.16	37.16	37.16	148.64	138.51
c. Others	4.43	7.32	33.44	26.43	53.36
Total:	73.23	87.21	85.24	276.99	228.36
Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
Net Sales / Income from Operations	73.23	87.21	85.24	276.99	228.36
2. Segment Results before Tax and Interest					
a. Healthcare	16.97	25.10	8.13	58.61	22.60
b. Rent on Leasehold land	37.16	36.93	37.16	148.64	138.51
c. Others	4.43	7.32	33.44	26.43	53.36
Total:	58.56	69.35	78.73	233.68	214.47
Less:					
Other Unallocable Expenditure					
Net off Unallocable Income	34.63	44.38	29.65	136.98	121.32
Total Profit / (loss) before Tax	23.93	24.97	49.08	96.69	93.15
3. Capital Employed (Segment Assets - Segment Liabilities)					
a. Healthcare	13.62	10.22	3.78	13.62	3.78
b. Rent on Leasehold land	(0.72)	(0.48)	0.21	(0.72)	0.21
c. Others	646.42	627.59	583.79	646.42	583.79
Total:	659.32	637.33	587.78	659.32	587.78

The above results were taken on record at a meeting of the Board of Directors held on May 20, 2023

Mumbai
20th May 2023


 By order of the Board
 Jeyavel B. Nadar
 Executive Director & CFO
 DIN No. 08163899




EMMESSAR BIOTECH & NUTRITION LTD			
Statements of Assets & Liabilities			
(Rs. In Lacs)			
	Particulars	As at 31st Mar 2023	As at 31st Mar 2022
A	ASSETS		
1	Non-current Assets		
	(a) Property, Plant & Equipment	139.72	145.51
	(b) Investment Property	60.70	61.63
	(c) Other Financial Assets	0.49	0.29
	(d) Deferred Tax Assets (net)	-	27.80
	Sub-total Non-current Assets	200.90	235.23
2	Current Assets		
	(a) Inventories	13.62	6.82
	(b) Investments	0.83	0.79
	(c) Trade Receivables	1.08	1.29
	(d) Cash & Cash equivalents	1.18	18.19
	(e) Bank balance other than cash & Cash Equi	518.02	440.21
	(f) Loans	0.88	0.59
	(g) Income tax assets (net)	7.14	1.32
	(h) Other Financial assets	9.01	11.42
	(i) Other current assets	41.62	5.51
	Sub-total Current Assets	593.37	486.14
	TOTAL ASSETS	794.27	721.37
B	EQUITY AND LIABILITIES		
1	SHAREHOLDER'S FUNDS:		
	(a) Equity Share Capital	499.61	499.61
	(b) Other Equity	166.85	117.29
	Sub-total Shareholder's funds	666.46	616.90
2	Non-current Liabilities		
	(a) Other Financial liabilities	61.42	61.42
	(b) Long Term Provisions	11.24	10.04
	(c) Deferred Tax Liability (net)	13.20	-
	Sub-total Non-current liabilities	85.86	71.46
3	Current Liabilities		
	(a) Borrowings	8.21	-
	(b) Trade payables	-	2.16
	(c) Other financial Liabilities	7.86	7.14
	(e) Other current liabilities	2.50	3.21
	(f) Short-term provisions	23.39	20.50
	Sub-total Current Liabilities	41.95	33.01
	TOTAL EQUITY AND LIABILITIES	794.27	721.37



EMMESSAR BIOTECH & NUTRITION LTD

Rupees in Lacs

CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2023		2022-23	2021-22
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit before Tax and Extraordinary Items	96.69	93.15
	Add/(-)Less: Depreciation	9.36	9.23
	Interest / Dividend	(23.64)	(20.92)
	Other comprehensive income	(1.14)	(0.99)
	Operating Profit / Loss before working Capital changes	81.28	80.48
	Adjustment for (Increase) / Decrease in operating Assets		
	Inventories	(6.80)	(0.09)
	Trade Receivables	0.21	269.72
	Non current loans and Income Tax Assets	(17.04)	(15.53)
	Current Assets - Loans and other assets	(36.39)	3.29
	Adjustment for Increase / (Decrease) in operating Liabilities		
	Non current provisions	1.20	1.13
	Trade Payables	(2.16)	(47.46)
	Borrowings and Other Financial Liabilities	8.93	(11.10)
	Other Current Liabilities	(0.72)	(26.72)
	Current Provisions	2.89	2.41
	Cash generated before tax payments	31.39	256.13
	Add: Income Tax Refund	11.23	0.00
	Less: Income tax paid	5.00	29.15
	Cash generated from operations	37.62	226.98
B	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	(2.63)	(30.56)
	Investments in Mutual Funds	(0.04)	(0.03)
	Interest / Dividend Received	26.05	13.93
	Investments in Fixed Deposits (maturing within 12 months)	(77.81)	(245.77)
	Deposits Received	(0.20)	0.99
	Net Cash inflow/(out flow) in Investing activities	(54.63)	(261.44)
C	CASH FLOW FROM FINANCING ACTIVITIES		
	Net Cash used in financing activities		
	Net increase in cash and cash equivalents	(17.00)	(34.45)
	Cash and cash equivalents as at the beginning of the year	18.19	52.64
	Cash and cash equivalents as at the end of the year	1.18	18.19



Tel : 022-2200 4465, 022-2206 7440
E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

V. Sankar Aiyar & Co.
CHARTERED ACCOUNTANTS
2-C, Court Chambers
35, New Marine Lines
Mumbai – 400 020

INDEPENDENT AUDITOR'S REPORT

To The Board of Directors of Emmessar Biotech & Nutrition Limited

Report on the Audit of Financial Results

Opinion

We have audited the accompanying financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter and year ended March 31, 2023, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- (i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the quarter and year ended 31 March, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements in India under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

Board of Director's Responsibilities for the Financial Results

These financial results have been prepared on the basis of the annual financial statements of the Company. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the annual financial results made by the Management.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the financial Results.

V. Sankar Aiyar & Co.

CHARTERED ACCOUNTANTS

Mumbai – 400 020

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Financial Results include the results for the quarter ended 31st March, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year.



For **V. Sankar Aiyar & Co.**

Chartered Accountants

(FRN 109208W)

ASHA
JAYANTIBH
AI PATEL

Digitally signed by
ASHA JAYANTIBHAI
PATEL
Date: 2023.05.20
16:30:36 +05'30'

(Asha Patel)

Partner

(M.No.166048)

UDIN:23166048BGUTEW7273

Place: Mumbai

Date: May 20, 2023